NASDAQ · PHARMACEUTICAL PREPARATIONS · MID CAP
Nanobiotix S.a. NBTX
8 fiscal years on record · EUR · FY2025 reported · SEC filings only
Growth
EUR 32.6M
Revenue, FY2025 · full 8-year series below
Revenue €M
Net income €M
FY2025 · Revenue 32.6 · Net income -24.0
Compound annual growth
Revenue compounded at +67.0% a year over five years.
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
−74 cents
lost on every revenue dollar
Operating margin
Net margin
FY2025 · Operating -33.2% · Net -73.5%
ROE
Not available in our data for this period.
The 8-year record
8 fiscal years
Every figure from documents filed with the SEC · EUR
EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.
row low → row highnegative
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue €B | 0.0 | −0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Operating income €B | −0.0 | −0.1 | −0.0 | −0.0 | −0.1 | −0.0 | −0.0 | −0.0 |
| EBITDA €B | · | · | · | · | · | · | · | · |
| Income tax €B | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Net income €B | −0.0 | −0.1 | −0.0 | −0.1 | −0.0 | −0.0 | −0.1 | −0.0 |
| Free cash flow €B | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 |
| EPS, diluted € | −0.50 | −1.44 | −1.08 | −1.64 | −1.35 | −1.38 | −2.35 | −1.55 |
| Dividend / sh € | · | · | · | · | · | · | · | · |
| Payout % | · | · | · | · | · | · | · | · |
| ROE % | · | · | · | · | · | · | · | · |
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Compare
This company against its peers
Nanobiotix S.a.vsSanofiSame industry: Pharmaceutical PreparationsNanobiotix S.a.vsGrifols SASame industry: Pharmaceutical PreparationsNanobiotix S.a.vsLakefront Biotherapeutics NVSame industry: Pharmaceutical PreparationsNanobiotix S.a.vsEvotec SESame industry: Pharmaceutical PreparationsNanobiotix S.a.vsAscendis Pharma A/SSame industry: Pharmaceutical PreparationsNanobiotix S.a.vsProQR Therapeutics N.v.Same industry: Pharmaceutical PreparationsNanobiotix S.a.vsInventiva S.a.Same industry: Pharmaceutical Preparations
Provenance
Company facts, as filed
How we verify · 0 failures in 32 reconciliationsAUDITED
Reconciled in 8 of 19 fiscal years. 44 checks could not be computed.
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inoutside the United States — SEC code I0
Fiscal year endsDecember 31
Data on record since2018